The Longevity Effects Of Psilocybin

Summary

Bryan Johnson describes a medically supervised, single-person experiment examining whether psilocybin might affect biological systems related to aging. The idea was prompted in part by an earlier study—whose authors are not named in the subtitles—that reportedly found psilocybin helped human cells live longer in laboratory dishes. Johnson’s team then reviewed the literature and designed an extensively measured protocol.

Experiment and measurements

Johnson took two large doses of dried Psilocybe mushrooms, three weeks apart:

• First dose: 4.67 g of B+ mushrooms, reported to contain 24.98 mg of psilocybin.
• Second dose: 5.35 g of the same strain, reported to contain 28 mg of psilocybin.

The team collected 249 baseline measurements before the first dose and added 136 more measurements for the second. Measures included brain activity, hormones, inflammation, metabolism, heart and stress markers, sexual function, DNA-related measures, and cellular aging.

The second session also included thermal imaging and continuous brain scans. Johnson says both sessions were medically supervised and conducted in a controlled setting.

Reported observations

The video presents these as preliminary observations from Johnson, not established effects of psilocybin:

• Stress hormones: Cortisol rose sharply for several hours after the first dose, then returned to baseline by evening. Five days later, morning cortisol was reported to be 42% lower and DHEA 45% lower. Similar changes were said to occur after the second dose.
• Brain activity: Brain scans showed reduced activity in the default mode network and increased communication among brain regions. The video describes this increased, less rigid activity as greater neural “entropy.” Some brain-scan changes reportedly remained three weeks after the first dose and appeared stronger after the second.
• Blood glucose: Continuous glucose-monitor data showed an 8% drop in mean blood glucose and an 11% drop in variability in the three days after the first dose. Estimated HbA1c fell from 4.7 to 4.4, according to the video. The presenter calls this the first documented human evidence of improved blood-sugar control after psilocybin.
• Inflammation: High-sensitivity C-reactive protein (hs-CRP), already low at 0.23, fell below the test’s detection limit of 0.15 five days after the first dose and reportedly remained suppressed after the second.
• Thermal imaging: During the second experience, core temperature reportedly rose by 1.5–2°F, with heat redistributed toward the body’s center. The team described this as the first thermal profile of an intense psilocybin experience.
• Gut microbiome: The team reported shifts in several microbial species, including decreases in species associated with stress, anxiety, or insulin resistance, and the appearance of a new species. The long-term meaning was stated to be unknown.
• Subjective experience: Johnson described increased sensory vividness, openness, connection, and a calmer emotional state. He said the experience did not diminish his commitment to his work.

Interpretation and limitations

The video argues that the reported changes across stress hormones, metabolism, inflammation, brain activity, and the microbiome may be relevant to aging. Johnson characterizes psilocybin as a potential longevity therapy, but the experiment does not establish that it slows aging or improves health generally. It involved one person, without a comparison group, and the findings may not apply to others.

The video says the magnitude and durability of the effects need further study and replication. Measurements of telomeres and epigenetic age were still pending.

The video also cautions that it is not an endorsement or recommendation to use psilocybin. It says the experiment was medically supervised and controlled, and notes that ordinary health fundamentals—sleep, nutrition, and movement—remain important.

Researchers and sources featured

• Bryan Johnson and his team, who conducted and reported the experiment.
• Kernel Flow, the neuroimaging device used for brain measurements; Johnson says he helped develop it.
• An unnamed study reporting longer survival of human cells in a laboratory dish after psilocybin exposure. The subtitles do not identify its researchers or publication.
• Metformin, mentioned as a comparison for blood-glucose control, not as a source of the experiment’s findings.

No individual researchers or scientific papers are named in the subtitles.